VVUS), a biopharmaceutical stock, as it seeks approval for its weight-loss drug Qnexa. We've described Qnexa as a potential blockbuster drug and see sense in a J.P. Morgan Securities note that advises investors to use …
Poor sales of Vivus (NASDAQ:VVUS) Pharmaceuticals’ obesity drug Qsymia, which was released in mid-September, have depressed the company’s stock price by 23 percent and contributed to a third-quarter net …
The stock could be poised to extend these losses, should history repeat itself. In the past 10 fourth quarters, MNKD has averaged a loss of 12.6%, and has been positive just once. In August, VVUS tagged its lowest …
Both Vivus VVUS, +1.77% and Arena Pharmaceutical ARNA ... I wrote an article back on December 21st of last year about my favorite drug stock. Here is a link to the article, if you missed it. The stock was trading at …
Instead of welcoming a critical view, a lot of longs prefer to ignore information that doesn’t confirm that they made an excellent decision buying the stock. This is fundamentally different than people who argue for the long …
Continue Reading Below VIVUS (VVUS) gapped up today, opening at $30.33 after closing the previous trading session at $26.46. Shares have risen 10.2%, trading at a volume of 14.9 million. The stock has been on an …
In its letter to the drug development company’s shareholders, First Manhattan Co. criticized the existing board for having negligible stock ownership, while the investment management firm owns 12 million shares in VIVUS, …
The stock’s 52-week high is $10.12. Share volume is nearly double the daily average of 400,000 shares traded. The royalty company had no specific news today but is feeling pressure from low crude prices. Vivus Inc. …
Common Stock Issuance is the amount of money the company generates when a company initially sold its common stock and preferred on the open market to investors. Access over 100 stock metrics like Beta, …
We rate Vivus Inc “Sell”, not just because of Santosh’s informed stock investment but also because our time momentum model says so. Vivus Inc’s share price dived by 38.89% in the last 200 days and is still going …